Wooree Bio Co.,Ltd (KOSDAQ:082850)
South Korea · Delayed Price · Currency is KRW 1,576.00
-9.00 (-0.57%)
At close: Jun 4, 2026
Wooree Bio Co.,Ltd Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,014,857 | 1,043,962 | 1,237,198 | 1,263,944 | 1,355,056 | 1,543,312 |
Other Revenue | -0 | -0 | - | -0 | - | - |
| 1,014,857 | 1,043,962 | 1,237,198 | 1,263,944 | 1,355,056 | 1,543,312 | |
Revenue Growth (YoY) | -18.38% | -15.62% | -2.12% | -6.72% | -12.20% | -4.93% |
Cost of Revenue | 921,095 | 949,533 | 1,119,187 | 1,148,606 | 1,241,417 | 1,427,899 |
Gross Profit | 93,762 | 94,430 | 118,012 | 115,337 | 113,639 | 115,412 |
Selling, General & Admin | 79,394 | 74,599 | 84,804 | 74,363 | 65,396 | 57,472 |
Research & Development | 10,816 | 11,108 | 11,439 | 8,398 | 7,019 | 7,382 |
Amortization of Goodwill & Intangibles | 380.47 | 386.15 | 375.98 | 315.99 | 372.6 | 530.3 |
Other Operating Expenses | 1,550 | 1,441 | 1,548 | 1,350 | 1,884 | 1,274 |
Operating Expenses | 97,897 | 93,489 | 102,812 | 89,355 | 79,398 | 72,995 |
Operating Income | -4,135 | 940.96 | 15,200 | 25,982 | 34,241 | 42,417 |
Interest Expense | -5,606 | -6,127 | -5,402 | -6,052 | -4,948 | -4,438 |
Interest & Investment Income | 3,440 | 3,469 | 4,365 | 3,834 | 1,632 | 427.15 |
Earnings From Equity Investments | -85.67 | 50.36 | -79.77 | -190.83 | -123.76 | -184.23 |
Currency Exchange Gain (Loss) | 4,136 | -722.62 | 8,637 | -1,908 | -116.95 | 4,510 |
Other Non Operating Income (Expenses) | 288.51 | -1,202 | 3,829 | 250.77 | 1,224 | 2,566 |
EBT Excluding Unusual Items | -1,963 | -3,592 | 26,548 | 21,917 | 31,909 | 45,298 |
Gain (Loss) on Sale of Investments | -27.87 | - | - | - | - | 188.71 |
Gain (Loss) on Sale of Assets | -209.36 | -142.36 | 317.61 | -187.34 | 117.01 | -206.37 |
Asset Writedown | -2,623 | -2,623 | -2,327 | - | - | - |
Pretax Income | -4,823 | -6,358 | 24,539 | 21,729 | 32,026 | 45,281 |
Income Tax Expense | 4,471 | 3,815 | 16,312 | 2,783 | 6,900 | 1,239 |
Earnings From Continuing Operations | -9,294 | -10,173 | 8,227 | 18,946 | 25,126 | 44,041 |
Net Income to Company | -9,294 | -10,173 | 8,227 | 18,946 | 25,126 | 44,041 |
Minority Interest in Earnings | 2,616 | 798.47 | -3,483 | -3,365 | -3,304 | -10,886 |
Net Income | -6,678 | -9,374 | 4,743 | 15,581 | 21,822 | 33,156 |
Net Income to Common | -6,678 | -9,374 | 4,743 | 15,581 | 21,822 | 33,156 |
Net Income Growth | - | - | -69.56% | -28.60% | -34.18% | 96.87% |
Shares Outstanding (Basic) | 47 | 47 | 47 | 47 | 46 | 44 |
Shares Outstanding (Diluted) | 47 | 47 | 47 | 47 | 46 | 48 |
Shares Change (YoY) | -0.65% | -0.47% | 0.07% | 1.95% | -2.87% | 5.70% |
EPS (Basic) | -141.51 | -198.57 | 100.00 | 330.98 | 469.36 | 750.13 |
EPS (Diluted) | -141.51 | -198.57 | 100.00 | 329.00 | 469.00 | 702.06 |
EPS Growth | - | - | -69.60% | -29.85% | -33.20% | 86.70% |
Free Cash Flow | 67,592 | 12,976 | -45,711 | 16,018 | 30,085 | 38,588 |
Free Cash Flow Per Share | 1432.37 | 274.88 | -963.73 | 337.94 | 647.10 | 806.13 |
Gross Margin | 9.24% | 9.04% | 9.54% | 9.13% | 8.39% | 7.48% |
Operating Margin | -0.41% | 0.09% | 1.23% | 2.06% | 2.53% | 2.75% |
Profit Margin | -0.66% | -0.90% | 0.38% | 1.23% | 1.61% | 2.15% |
Free Cash Flow Margin | 6.66% | 1.24% | -3.69% | 1.27% | 2.22% | 2.50% |
EBITDA | 23,368 | 28,612 | 42,731 | 57,832 | 70,435 | 77,974 |
EBITDA Margin | 2.30% | 2.74% | 3.45% | 4.58% | 5.20% | 5.05% |
D&A For EBITDA | 27,503 | 27,671 | 27,531 | 31,850 | 36,194 | 35,557 |
EBIT | -4,135 | 940.96 | 15,200 | 25,982 | 34,241 | 42,417 |
EBIT Margin | -0.41% | 0.09% | 1.23% | 2.06% | 2.53% | 2.75% |
Effective Tax Rate | - | - | 66.47% | 12.81% | 21.54% | 2.74% |
Advertising Expenses | - | 6,519 | 8,170 | 9,177 | 8,633 | 3,642 |